Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

13.6%

66 terminated/withdrawn out of 486 trials

Success Rate

78.7%

-7.8% vs industry average

Late-Stage Pipeline

16%

79 trials in Phase 3/4

Results Transparency

0%

0 of 244 completed trials have results

Key Signals

102 recruiting57 terminated9 withdrawn

Enrollment Performance

Analytics

N/A
218(66.5%)
Phase 3
55(16.8%)
Phase 2
24(7.3%)
Phase 4
24(7.3%)
Phase 1
7(2.1%)
328Total
N/A(218)
Phase 3(55)
Phase 2(24)
Phase 4(24)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (486)

Showing 20 of 486 trials
NCT02086253Not ApplicableCompleted

Role of Endothelin-1 in Flow-mediated Dilatation

Role: lead

NCT06822751Phase 3Not Yet Recruiting

FOsfomycin for Male Urinary Tract Infection

Role: lead

NCT01054053Phase 4Completed

Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 Patients Have to be Vaccinated MenBVac®

Role: lead

NCT04048213Completed

The Becoming of Children With Doose Syndrome

Role: collaborator

NCT03926377Phase 4Completed

Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid

Role: collaborator

NCT01621945Phase 3Completed

Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 in Patients Having to be Vaccinated MenBVac® (Extension EFFIVAC)

Role: lead

NCT03295383Phase 3Active Not Recruiting

Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid

Role: lead

NCT06559033Recruiting

Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS

Role: lead

NCT07151274Recruiting

Impact of Ehlers-Danlos Syndrome on Gynaecological Health

Role: lead

NCT07535944Not Yet Recruiting

Prospective Exploration of Vascular Complications Associated With the Use of Immune Checkpoint Inhibitors

Role: lead

NCT06489912Recruiting

Overview of the Mental Health of Adolescents in Therapeutci, Educational and Pedagogical Facilities in France

Role: lead

NCT02006446Not ApplicableCompleted

Relationship Between Sperm Head Vacuoles and Sperm DNA Alterations in Infertile Men

Role: lead

NCT01469962Not ApplicableCompleted

Evaluation of Liver Fibrosis Following Surgical-induced Weight Loss

Role: lead

NCT06291116Phase 2Recruiting

Safety of RotigotiNe in Patients With Autosomal Dominant Polycystic Kidney Disease

Role: lead

NCT06291077Phase 4Recruiting

Comparison of the Effects of Belatacept and Anticalcineurins on Endothelial Function in Renal Transplant Patients - <BELAFENDO>

Role: lead

NCT06446557Phase 3Not Yet Recruiting

De-scalation or swItch of Treatment According to Circulating tuMOr DNA Variation After 2 Cycles of Doublet Chemotherapy Plus Targeted Agent in Metastatic Unresectable Colorectal Cancer

Role: lead

NCT06123169Phase 3Not Yet Recruiting

Postoperative Anti-infective Strategy Following Pancreaticoduodenectomy in Patients With Preoperative Biliary Stent

Role: lead

NCT06560723Not ApplicableNot Yet Recruiting

Implementation of a Personalised Health Plan (PHP) on Patient Quality of Life Score at 2-year Follow-up

Role: lead

NCT07247500Not ApplicableNot Yet Recruiting

Impact of Reventilation After One-Lung Ventilation in Thoracic Surgery (OLVREEXP)

Role: lead

NCT05702996Phase 3Withdrawn

Study Evaluating the Efficacy of Eculizumab in the Treatment of Gemcitabine-induced Thrombotic Microangiopathies

Role: lead